
Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab
Keywords: Endoscopic; TNF Antagonist; Therapeutic Drug Monitoring; Optimization; ATI; antibody to infliximab; CD; Crohn's disease; IBD; inflammatory bowel disease; IQR; interquartile range; TAXIT; Trough Concentration Adapted Infliximab Treatment; TDM; therapeuti